Craft
  • Home
  •  / Kala Pharmaceuticals
Kala Pharmaceuticals

Kala Pharmaceuticals

Patents (US)

6

FY, 2016

Revenue

$45 K

FY, 2015

Market Capitalization

$18.8 M

2022-09-20

Kala Pharmaceuticals Summary

Company summary

Overview
Kala Pharmaceuticals is a clinical-stage pharmaceutical company focused on innovative nanoparticle-based treatments for ocular diseases affecting both the front and back of the eye. It utilizes its proprietary mucus-penetrating particle (MPP) technology to develop topical ophthalmic formulations. The company also researches a small molecule receptor tyrosine kinase inhibitor (RTKi) program as a potential topical treatment of wet age-related macular degeneration (AMD).
Type
Public
Founded
2009
HQ
Watertown, MA, US | view all locations
Website
https://www.kalarx.com/
Cybersecurity rating
ESG rating
out of 100 | View all ESG data
Sectors

Key people

  • Mark Iwicki

    Mark Iwicki, Chairman, Chief Executive Officer

  • Kim Brazzell

    Kim Brazzell, Chief Medical Officer, Head of Research and Development

  • Mary Reumuth

    Mary Reumuth, Chief Financial Officer

  • Todd Bazemore

    Todd Bazemore, President, Chief Operating Officer

Operating MetricsView all

Patents (US)

6

FY, 2016

Patents (Foreign)

2

FY, 2016

Patent Applications

101

FY, 2016

LocationsView all

1 location detected

  • Watertown, MA HQ

    United States

    490 Arsenal Way, Suite 120

Footer menu